Sencilia has raised $2.2M to make low-flow infusion therapy visible - a problem that has quietly persisted in neonatal and critical care. At very low flow rates, no infusion system today can directly confirm the flow reaching the patient, and pressure-based occlusion alarms can take hours to flag a blocked or disconnected line while drugs like vasopressors and insulin wear off within minutes.
The Groningen-based company's sensor, Rely-V®, clips onto standard IV tubing and measures flow inside it down to 0.1 mL/h without touching the fluid, designed to detect disruptions within about a minute. Sencilia, a 2021 spin-out of the University of Groningen, is backed in this round by Future Tech Ventures, NVNOM, imec.istart, RUG Ventures, Triade and Rabobank. Rely-V® is an investigational device, not yet CE marked or FDA-approved.
